B+
Bull case
30%
Probability
Target price
$130.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
RVTY
RevvityDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Q2 result showed stronger diagnostics demand, adjusted margin expansion, and a raised FY26 pro forma outlook. Diagnostics pro forma organic growth was 11%, while adjusted operating margin expanded to 29.3% company-wide [#SEC-8K-2026-08-04].
Posture
Defensive
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-10-25.
What can break
China Immunodiagnostics represented approximately 6% of FY2025 revenue; divestiture execution and regulatory approval remain outstanding through the expected 2027 close [#SEC-8K-2026-08-04].
Momentum
97
Value
60
Sentiment
29
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $121.00 · Bull $130.00 · Bear $100.00Analysis 2026-08-07; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $149.36
Why
Momentum97 · Δ7d -2.3
Value60 · Δ7d -0.3
Sentiment29 · Δ7d -2.7
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-10-25.
- • Value remains the lead driver in the composite, 7D delta -0.3.
Contradictions & invalidation
- • China Immunodiagnostics represented approximately 6% of FY2025 revenue; divestiture execution and regulatory approval remain outstanding through the expected 2027 close [#SEC-8K-2026-08-04].
- • Life Sciences pro forma organic revenue declined 3% and segment adjusted margin fell to 31.1% from 31.6% [#SEC-8K-2026-08-04].
- • Life Sciences pro forma organic revenue declined 3%, and Q2 adjusted EPS included approximately $0.11 from tariff refunds.
Catalyst clock
2026-08-04
Q2 2026 beat and raised FY26 outlook
Lead driver: Value · See fundamentals
Momentum
97
8% active weight
Current posture
7d trendSoftening
Δ7d
-2.3
Δ21d
-0.2
Value
60
47% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-1.0
Sentiment
29
45% active weight
Current posture
7d trendSoftening
Δ7d
-2.7
Δ21d
-8.2
Why this grade
Composite grade D. Momentum 97.3 / Value 60.5 / Sentiment 28.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-07. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$121.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$100.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$17.72B
Beta
1.06
Shares Out
111.59M
P/E (TTM)
52.3
P/S (TTM)
4.11
P/FCF (TTM)
24.94
Rev YoY
+1.3%
EPS YoY
-0.9%
Gross Margin
+48.2%
Op Margin
+15.5%
Net Debt
$2.48B
Current Ratio
1.80
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data